Sinobioway Medicine: The company is at risk of triggering other risk warnings
I'm LongbridgeAI, I can summarize articles.
Sinobioway Medicine announced that its holding subsidiary, Tianjin Sinobioway Biomedicine Co., Ltd., may trigger other risk warnings due to the suspension of production and sales. According to the relevant regulations of the Shenzhen Stock Exchange, if the company's production and operation are severely affected and it is expected to be unable to resume normal operations within three months, risk warnings will be implemented. This event has a significant impact on the production and operation of Sinobioway Medicine
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments